Valeant shares hit 2017 high on completion of US$819.9 million sale of Dendreon

Valeant shares hit 2017 high on completion of US$819.9 million sale of Dendreon

LAVAL, Que. — Shares in Valeant Pharmaceuticals hit a new high for the year on the Toronto Stock Exchange this morning after the company completed the sale of its Dendreon subsidiary for US$819.9 million cash.

Valeant shares traded as high as $23.75 after markets opened this morning, about six per cent above where it closed Wednesday.

The stock has been climbing since April 21, when Valeant closed at $11.45, as investors have gained confidence in the company’s ability to reduce its debt.

Proceeds from the sale of Dendreon Pharmaceuticals to China-based Sanpower Group will be used to repay a term loan.

Valeant’s shares remains far below their value two year ago, when they traded for more than $300 per share for several weeks before they plunged amid questions about the sales it generated through Philidor Rx Services — an online pharmacy.

The Canadian Press

…………………………………………………………………………………………………………….……………………………The_Quebec_Book_cover_Promo_small

Would you like to support a project based right here in Quebec?

This book is being co-authored by two people who are passionate about Quebec and everything it has to offer. One of the authors moved to the region some years ago while the other was born and raised in Quebec.

The Québec Book is a unique guide for anyone interested in learning about Quebec culture and the language spoken here. You could be someone visiting Québec, planning to move to Québec, or already living here. Or maybe you’re a native English speaker, a native French speaker, or a speaker of any other language for that matter.

Pre-Order The Québec Book Now and Receive a Bonus!

Categories: Business

About Author

Write a Comment

Only registered users can comment.